Japanese Pharmacology & Therapeutics（JPT）
Vol. 26 Suppl. 4 1998
All papers include English abstract **In English
A single dose toxicity study of mizolastine in rats and cynomolgus monkeys
M. Bezancon, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s565-71**
A 6-month oral toxicity study of mizolastine in rats
M. Bezancon, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s573-90**
A 6-month oral toxicity study of mizolastine in cynomolgus monkeys
M. Bezancon, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s591-610**
A 12-month oral toxicity study of mizolastine in rats with a recovery period of one month
M. Bezancon, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s611-31**
A 12-month oral toxicity study of mizolastine in cynomolgus monkeys with a recovery period of one month
M. Bezancon, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s633-54**
Antigenicity study of mizolastine
H. Wada, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s655-62
Mutagenicity and clastogenicity studies with mizolastine
Y. Iwase, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s663-72**
Anti-allergic effects of mizolastine
N. Yamada, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s673-9*
Anti-histamine effects of mizolastine
N. Yamada, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s681-5*
Inhibitory effects of mizolastine on the release of mediators and antagonistic effects against mediators
N. Yamada, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s687-94*
Inhibitory effects of mizolastine on cytokine productions
K. Funayama, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s695-9*
Effects of mizolastine on the experimental model of allergic rhinitis in rats
N. Yamada
Jpn Pharmacol Ther 1998 26(Suppl.4) s701-6*
Effects of mizolastine on the experimental model of allergic rhinitis in rats
N. Yamada, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s707-10*
Inhibitory effects of mizolastine on 5-lipoxygenase
K. Sudo, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s711-3*
H1-receptor antagonism of mizolastine on the isolated ileum of the guinea pig
Richard S, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s715-9*
Characterization of mizolastine in radioligand binding studies in vitro
Schoemaker H, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s721-32*
Anti-inflammatory properties of mizolastine after oral administration on arachidonic acid-induced cutaneous reaction in the rat
Pichat P, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s733-8*
Antihistamine action of mizolastine in comparison with that of terfenadine in the dog
Prouteau M, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s739-43*
Metabolites of mizolastine
－Their affinity for H1 receptors and in vivoanti-histamine properties－
Arbilla S, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s745-7*
General pharmacological studies of mizolastine
Y. Watanabe, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s749-67*
Lack of sedative potential of mizolastine, a novel selectiveH1-receptor antagonist, on the sleep wakefulness cycle in rats
Depoortere H.
Jpn Pharmacol Ther 1998 26(Suppl.4) s769-78*
Effects of mizolastine on respiratory function in the rat
Levrier J, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s779-85*
Evaluation of hemodynamic effects of mizolastine following intravenous dosing in anesthetized dogs
Richard S, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s787-800*
Cardiovascular profile of mizolastine, a H1-receptor antagonist and potential anti-allergic agent, in pentobarbital anesthetized Rats
Pierre F
Jpn Pharmacol Ther 1998 26(Suppl.4) s801-5**
Electrocardiographic effects of mizolastine and terfenadine in conscious dogs
－Modifications induced by ketoconazole pretreatment－
Lainee P, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s807-17**
Evaluation of the effects of mizolastine on coagulation factors in rats
Pattano N
Jpn Pharmacol Ther 1998 26(Suppl.4) s819-21**
General pharmacological studies of mizolastine metabolites
Y. Watanabe, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s823-8*
Pharmacokinetic studies of 2-［［1-［1-［(4-fluorophenyl) methyl］-1H-benzimidazol-2-yl］piperidin-4-yl］methylamino］pyrimidin-4(1H)-one(mizolastine)in rats(1)
－Absorption, distribution, metabolism and excretion after single oral or intravenous administration－
N. Hisanaga, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s829-52*
Pharmacokinetic studies of 2-［［1-［1-［(4-fluorophenyl) methyl］-1H-benzimidazol-2-yl］ piperidin-4-yl］methylamino］pyrimidin-4(1H)-one(mizolastine)in rats(2)
－Absorption, distribution, metabolism, excretion and effects of mizolastine on hepatic drug metabolizing enzymes after repeated oral administration－
N. Hisanaga, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s853-67*
Pharmacokinetic studies of 2-［［1-［1-［(4-fluorophenyl) methyl］-1H-benzimidazol-2-yl］ piperidin-4-yl］methylamino］pyrimidin-4(1H)-one(mizolastine)in rats(3)
－Feto-placental transfer and excretion into milk－
N. Hisanaga, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s869-78*
Pharmacokinetic studies of 2-［［1-［1-［(4-fluorophenyl) methyl］-1H-benzimidazol-2-yl］ piperidin-4-yl］methylamino］pyrimidin-4(1H)-one(mizolastine)
－Protein binding in rat, monkey and human－
M. Yamamoto, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s879-87*
Pharmacokinetic studies of mizolastine(2-［［1-［1-［（4-fluorophenyl)methyl］-1H-benzimidazol-2-yl］piperidin-4-yl］methylamino］pyrimidin-4(1H)-one)
in cynomolgus monkeys
－Absorption, metabolism and excretion after single administration－
Pouliquen I, et al.
Jpn Pharmacol Ther 1998 26(Suppl.4) s889-901**